肝素酶及Ki-67在非小细胞肺癌中的表达及临床意义

摘要

背景与目的 已有的研究表明,肝素酶与Ki-67抗原与肺癌的发生和转移有关,本研究通过检测非小细胞肺癌(Non-small cell lung cancer,NSCLC)组织中肝素酶(heparanase,Hpa)和Ki-67的表达,以探讨他们的临床意义及相互关系.方法 采用免疫组化方法 (S-ABC法和S-P法)检测70例NSCLC和20例同期良性病变肺组织中肝素酶和Ki-67的表达.结果 肝素酶和Ki-67的阳性表达率分别为72.9%和85.7%,而正常肺组织中两者均无表达;肝素酶表达水平与患者TNM分期及淋巴结转移有关(P=0.044,P=0.001);Ki-67的表达水平与原发肿瘤大小、组织学类型、癌细胞分化程度、淋巴结转移及TNM分期有关(P<0.05);肝素酶和Ki-67的表达差异无统计学意义(P=0.323).结论 肝素酶和Ki-67参与了肺癌的发生和发展,并与预后相关;而肝素酶和Ki-67的表达无相关性,两者可能通过不同的机制参与了肿瘤的发生和发展.%Background and objective It has been proven that heparanase and Ki-67 had relationship with occur-rence and metastasis in lung cancer. The aim of this work was to investigate the expressions of heparanase and Ki-67 and to ex-plore their clinical significance and mutual relations in non-small cell lung cancer (NSCLC). Methods Immunohistochemical method was used to detect the heparanase and Ki-67expression in the routinely paraffin-embedded sections of surgical specimen of 70 cases with NSCLC and 20 ones with normal lung tissues. Results Heparanase and Ki-67 were highly expressed in lung cancer tissues (72.996 and 85.796) while negative in epithelia of normal lung tissues. The expression of heparanase was signifi-cantly correlated with TNM stage (P=0.044) and lymphatic metastasis (P=0.001). The expression of Ki-67 was significantly cor-related with tumor size (P=0.03) and histology type (P=0.001) and differentiation (P=0.01) and lymphatic metastasis (P=0.01) and TNM stage (P=0.043). The expression ofhaparanase and Ki-67 was no significant difference (P=0.323). Conclusion Hepa-ranase and Ki-67 were involved in the occurrence and development of lung cancer and they may predict patients prognosis, while the expression of heparanase and Ki-67 had no association with NSCLC, which may contribute to the different mechanisms involved in tumor occurrence and development.